» Articles » PMID: 33445874

The Use of Alternative Strategies for Enhanced Nanoparticle Delivery to Solid Tumors

Overview
Journal Chem Rev
Specialty Chemistry
Date 2021 Jan 15
PMID 33445874
Citations 106
Authors
Affiliations
Soon will be listed here.
Abstract

Nanomaterial (NM) delivery to solid tumors has been the focus of intense research for over a decade. Classically, scientists have tried to improve NM delivery by employing passive or active targeting strategies, making use of the so-called enhanced permeability and retention (EPR) effect. This phenomenon is made possible due to the leaky tumor vasculature through which NMs can leave the bloodstream, traverse through the gaps in the endothelial lining of the vessels, and enter the tumor. Recent studies have shown that despite many efforts to employ the EPR effect, this process remains very poor. Furthermore, the role of the EPR effect has been called into question, where it has been suggested that NMs enter the tumor active mechanisms and not through the endothelial gaps. In this review, we provide a short overview of the EPR and mechanisms to enhance it, after which we focus on alternative delivery strategies that do not solely rely on EPR in itself but can offer interesting pharmacological, physical, and biological solutions for enhanced delivery. We discuss the strengths and shortcomings of these different strategies and suggest combinatorial approaches as the ideal path forward.

Citing Articles

Recent advances in the bench-to-bedside translation of cancer nanomedicines.

Liu Y, Zhang Y, Li H, Hu T Acta Pharm Sin B. 2025; 15(1):97-122.

PMID: 40041906 PMC: 11873642. DOI: 10.1016/j.apsb.2024.12.007.


Lipoic acid-boronophenylalanine-derived multifunctional vesicles for cancer chemoradiotherapy.

Dai L, Liu J, Yang T, Yu X, Lu Y, Pan L Nat Commun. 2025; 16(1):1329.

PMID: 39900898 PMC: 11790874. DOI: 10.1038/s41467-025-56507-4.


An Albumin-Photosensitizer Supramolecular Assembly with Type I ROS-Induced Multifaceted Tumor Cell Deaths for Photodynamic Immunotherapy.

Zhang J, Jiao D, Qi X, Zhang Y, Liu X, Pan T Adv Sci (Weinh). 2025; 12(9):e2410405.

PMID: 39804949 PMC: 11884554. DOI: 10.1002/advs.202410405.


Nanoformulated phytochemicals in skin anti-aging research: an updated mini review.

Uriostegui-Pena A, Torres-Copado A, Ochoa-Sanchez A, Luna-Barcenas G, Sahare P, Paul S 3 Biotech. 2025; 15(1):31.

PMID: 39760004 PMC: 11699038. DOI: 10.1007/s13205-024-04197-y.


Systematic review: Mechanisms of photoactive nanocarriers for imaging and therapy including controlled drug delivery.

Zhang Y, Qiu Y, Karimi A, Smith B Eur J Nucl Med Mol Imaging. 2024; 52(4):1576-1595.

PMID: 39722062 PMC: 11849580. DOI: 10.1007/s00259-024-07014-z.


References
1.
Min Y, Caster J, Eblan M, Wang A . Clinical Translation of Nanomedicine. Chem Rev. 2015; 115(19):11147-90. PMC: 4607605. DOI: 10.1021/acs.chemrev.5b00116. View

2.
DeNardo S, DeNardo G, Miers L, Natarajan A, Foreman A, Gruettner C . Development of tumor targeting bioprobes ((111)In-chimeric L6 monoclonal antibody nanoparticles) for alternating magnetic field cancer therapy. Clin Cancer Res. 2005; 11(19 Pt 2):7087s-7092s. DOI: 10.1158/1078-0432.CCR-1004-0022. View

3.
Gormley A, Malugin A, Ray A, Robinson R, Ghandehari H . Biological evaluation of RGDfK-gold nanorod conjugates for prostate cancer treatment. J Drug Target. 2011; 19(10):915-24. PMC: 9068228. DOI: 10.3109/1061186X.2011.623701. View

4.
Peiris P, He F, Covarrubias G, Raghunathan S, Turan O, Lorkowski M . Precise targeting of cancer metastasis using multi-ligand nanoparticles incorporating four different ligands. Nanoscale. 2018; 10(15):6861-6871. PMC: 5908762. DOI: 10.1039/c8nr02513d. View

5.
Nakahara T, Norberg S, Shalinsky D, Hu-Lowe D, McDonald D . Effect of inhibition of vascular endothelial growth factor signaling on distribution of extravasated antibodies in tumors. Cancer Res. 2006; 66(3):1434-45. DOI: 10.1158/0008-5472.CAN-05-0923. View